NGM Biopharmaceuticals

NGM Biopharmaceuticals

Verified
A clinical-stage biopharmaceutical company which engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases

Launch date
Employees
Ownership
Market cap
$436m
Net debt
$293m
Firm valuation
$142m (Public information from Nov 2022)
San Francisco California (HQ)
  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
$55.4mSeries B
$50mSeries C
$106mSeries E
$57.5mSeries D
N/AN/AIPO
N/A$125mPost IPO Equity
Total Funding$295m

Recent News about NGM Biopharmaceuticals

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.